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Background: Although in patients with COPD, the approach to daytime hypoxemia using
long-term oxygen therapy (LTOT) is established, the best approach to transient nocturnal
desaturation varies among clinicians. An understanding of the prevalence of nocturnal desa-
turation in COPD, in the absence of other respiratory co-morbidities, is an important step
towards its standardized management.
Methods: We conducted a 5 site cross-sectional study of stable patients with COPD and mild-to-
moderate daytime hypoxemia (PaO2 56e69 mmHg). Nocturnal saturation was monitored using
home oximetry on 2 occasions over a 2-week period. Patients were classified in 3 categories:
(A) no significant nocturnal desaturation; (B) significant nocturnal desaturation without
evidence of sleep apnea; (C) significant nocturnal desaturation with evidence of sleep apnea.
Results: In 128patients (meanFEV1: 37%predicted),wenotedanexcellent test-retest reliability
between the 2 oximetries. Forty-nine patients (38%) were classified as nocturnal desaturators
without evidence of sleep apnea, and 20 patients (16%) were classified as desaturators with
evidence of sleep apnea. Nocturnal desaturation without sleep apnea could not be predicted
by any patient characteristic or physiological measure.
Conclusions: A significant proportion (38%) of patients with moderate-to-severe COPD who do
not qualify for home oxygen therapy based on their daytime PaO2 have nocturnal oxygen desa-
turation without evidence of sleep apnea. Home oximetry is an effective practical method for
screening this population.
ª 2011 Elsevier Ltd. All rights reserved.656 4747; fax: þ1 418 656 4762.
.ulaval.ca (Y. Lacasse).
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1332 Y. Lacasse et al.Introduction Home nocturnal oximetry and definition ofSeveral studies have demonstrated oxygen desaturation
during sleep in patients with COPD.1e8 Two landmark mul-
ticentre studies included patients with marked daytime
hypoxemia qualifying for long-term oxygen therapy (LTOT).
In subsequent studies of patients not qualifying for LTOT,
the populations were heterogeneous and the definition of
desaturation varied. Moreover, subjects were not evaluated
under usual conditions of sleep, but underwent formal
respiratory polysomnograms.3,6e8
There is limited information regarding the extent to
which patients with moderate and severe COPD not quali-
fying for LTOT experience transient nocturnal desaturation.
One of the reasons for this situation is that the current
definition of “significant nocturnal oxygen desaturation” is
arbitrary and still controversial. Nevertheless many physi-
cians will prescribe nocturnal supplemental oxygen for such
patients although the beneficial effects of this therapy have
yet to be confirmed. Workshops of the National Heart, Lung,
and Blood Institute (NHLBI) on the needs and opportunities
for clinical research in COPD identified nocturnal oxygen
therapy as a research priority, in order to inform clinical
decision making with regard to home oxygen therapy.9,10 It is
therefore important to obtain an accurate estimate of the
prevalence of nocturnal desaturation in this population prior
to initiating clinical trials of nocturnal oxygen therapy.
Therefore, the primary objective of this study was to
determine the proportion of nocturnal oxygen desaturators
in a population of patients with COPD and mild to moderate
daytime hypoxemia. Our secondary objectives were (1) to
determine, in a pilot study, the accuracy of home nocturnal
oximetry to distinguish between sleep apnea and nocturnal
oxygen desaturation alone, and (2) to examine the repro-
ducibility (test-retest reliability) of home oximetry and the
concordance of its interpretation between respiratory
clinicians and a respiratory sleep specialist.MethodsPatients
This study took place in 5 Canadian outpatient respiratory
clinics (Hoˆpital Laval, Que´bec; West Park Healthcare
Centre, Toronto; Montreal Chest Institute; Hoˆtel-Dieu de
Le´vis and Ottawa Hospital), all of which offer a wide range
of health care services to patients with moderate-to-severe
COPD.
We included patients with (1) a diagnosis of COPD sup-
ported by a history of past or current smoking and
obstructive lung disease with an FEV1 < 60% predicted and
an FEV1/FVC < 70%; and (2) mild-to-moderate daytime
hypoxemia with a daytime PaO2 measured in a sitting
position in the range of 56e69 mmHg. Patients were
excluded if (1) they had experienced an acute exacerbation
within 6 weeks, (2) were receiving LTOT, (3) had a prior
diagnosis of sleep apnea, (4) had morbid obesity (body mass
index > 40 kg/m2), or (5) had any cardio-respiratory co-
morbidity (such as left heart failure) that might influence
the validity of the results.“nocturnal oxygen desaturation”
After obtaining informed consent, each patient underwent
two home oximetries over a 2 week period, using a digital
recording system (Palmsat 2500, Nonin Medical Inc., Ply-
mouth, MN, USA) for nocturnal saturation (SaO2) monitoring
and accepting a minimum recording time of 4 h. Nocturnal
desaturation was defined as 30% of the recording time
(time in bed) with a transcutaneous SaO2 < 90%.
8,11We also
noted the mean number of desaturations  3% per hour
(desaturation index), the baseline saturation, and the
average saturation over the entire tracing.
Each patient was classified into categories based on the
recording time with an SaO2 < 90% along with a visual
inspection of the printed report. They were classified as
having (1) no significant nocturnal desaturation (<30% time
with SaO2 < 90% for both oximetries); (2) significant
nocturnal desaturation (>30% time with SaO2 < 90% on
either of the oximetries) without evidence of associated
sleep apnea (no periodic variation in saturation) (Fig. 1A);
and (3) significant nocturnal desaturation (>30% time with
SaO2 < 90% on either of the oximetries) with evidence of
associated sleep apnea (cyclical changes in saturation as
well as desaturation on either of the oximetries) (Fig. 1B).12
All reports were reviewed by a respiratory sleep specialist
(FS) with extensive experience in oximetry assessment,
who was unaware of the diagnosis submitted by the other
investigators.
Pilot study: validation of home oximetry in
nocturnal desaturators
In a subgroup of nocturnal desaturators (i.e., patients with
>30% time with SaO2< 90% on either of the oximetries,
regardless of the suggestion of sleep apnea on oximetry
tracing), we conducted a blind comparison of home
nocturnal oximetry and laboratory polysomnography
obtained within 2 weeks of the second home nocturnal
oximetry. This study was conducted in a single centre
(Quebec). The polysomnographic recordings included
continuous acquisition of electroencephalogram, electro-
occulogram, submental electromyogram, naso-oral airflow
with thermistors, nasal pressure with nasal cannula), chest
and abdominal movements with impedance plethysmog-
raphy (RespitraceÆ, Ambulatory Monitoring Inc, Ardsley,
NY), electrocardiogram, and breath sounds by means of two
microphones connected to a calibrated sound analyzer.
Sleep position was continuously assessed by the attending
technician. All variables were digitally recorded (Sandman
EliteTM system, Mallinckrotd, Kenilworth, NJ). Sleep apnea
was considered to be significant when the apnea/hypopnea
index  15/h.
Other measures
Within 1 month of the first nocturnal oximetry, we extrac-
ted baseline clinical information from the medical record
(anthropometric measures, current medications, pulmo-
nary function tests) and obtained arterial blood gases while
patients were seated and breathing room air. In all sites,
Figure 1 Nocturnal oximetry tracings in patients with COPD not qualifying for LTOT. (A) Significant nocturnal oxygen desaturation
(>30% of the recording time with a saturation < 90%) with non-periodic variation in saturation throughout sleep. This tracing is not
suggestive of sleep apnea. (B) Significant nocturnal oxygen desaturation with cyclical changes in saturation suggesting sleep apnea.
Nocturnal oxygen in COPD 1333lung function measurements were made in keeping with the
American Thoracic Society and European Respiratory
Society guidelines.13e15Statistics
Descriptive statistics (proportions or means and standard
deviations, and associated 95% confidence intervals [CI])
were used to describe the study population. We examined
the reproducibility (test-retest reliability) of the oximetry by
correlating parameters obtained on the two recordings
(Time 1 vs. Time 2) using intra-class coefficients of correla-
tion. In the pilot sudy, we computed the proportion of true
positives and true negatives from home nocturnal oximetry
for the diagnosis of sleep apnea, with the result of the
laboratory polysomnography considered as the gold stan-
dard. The concordance between the patient classification by
the investigators in each site and the respiratory sleep
specialist was measured using the weighted Kappa
statistic.16 Final classification was according to the special-
ist’s opinion. Clinical characteristics of the desaturators,
both with and without evidence of sleep apnea and the non-
desaturators, were compared using 2-tailed Fischer’s exact
tests for the categorical variables and analyses of variance
for the continuous variables. Finally, we conducted logistic
regression analyses using the patients’ baseline character-
istics as possible predictors of the dependent variable,
nocturnal oxygen desaturation without evidence of sleep
apnea. In these analyses, given the multitude of comparisons
involved, statistical significance was set at the 0.01 level.
Preliminary data obtained from a small and independent
convenience sample of patients (n Z 12) indicated that
about 25% of the patients with moderate-to-severe COPD
meeting the inclusion criteria of our study would meet our
definition of “nocturnal desaturation without evidence ofsleep apnea” (unpublished data). We determined that
a sample size of 128 patients was needed to ensure a 95%
confidence interval of 7.5% around the final estimate of
the proportion of desaturators.17
Results
Patients
Of 245 patients screened, 128 completed the study.
Excluded patients were as follows: daytime PaO2> 69 mmHg
(n Z 51), refused to participate (n Z 41), recent acute
exacerbation (n Z 6), FEV1/FVC or FEV1 > 70% predicted
(n Z 5), use of oxygen (n Z 3), previous diagnosis of sleep
apnea (n Z 3), diffuse bronchiectasis as the main cause of
obstructive lung disease (n Z 2), BMI > 40 kg/m2 (n Z 2),
and other reasons (n Z 3). Only 1 eligible patient withdrew
before obtaining the second oximetry. The baseline char-
acteristics of the 128 patients who completed the study are
summarized in Table 1. On average, they had severe COPD
(FEV1 36  11% predicted, GOLD stage IV18) and moderate
hypoxemia (PaO2 65  4 mmHg).
Validation of home oxymetry in nocurnal
desaturators
Ten consecutive patients with nocturnal oxygen desatura-
tion underwent laboratory polysomnography. Sleep apnea
was diagnosed by polysomnography in 3 of the 5 patients
who were classified by the sleep specialist as nocturnal
desaturators with evidence of sleep apnea on home oxime-
try. Five were classified as desaturators without evidence of
associated sleep apnea on home oximetry; in all 5 patients,
sleep apnea was ruled out by polysomnography.
Table 1 Baseline characteristics (n Z 128).
Age, years (SD) 70 (8)
Gender, number of men (%) 49 (38%)
Body mass index, kg/m2 (SD) 25 (6)
Current smokers, number (%) 21 (16%)
Pack-years, mean (SD) 50 (25)
Medication, number (%)
Theophyline 21 (16%)
Tiotropium 104 (81%)
Long acting beta-agonists (LABA) alone 35 (27%)
Inhaled steroids (ICS) alone 5 (4%)
Combinations (LABA þ ICS) 58 (45%)
Prednisone 7 (5%)
pH, (SD) 7.42 (0.03)
PaCO2, mmHg (SD) 43 (5)
PaO2, mmHg (SD) 65 (4)
Hemoglobin, g/l (SD) 145 (14)
Hematocrit, % (SD) 0.44 (0.04)
FEV1, % predicted (SD) 36 (11)
FVC, % predicted (SD) 78 (20)
FEV1/FVC, % (SD) 36 (11)
FRC, % predicted (SD) 164 (34)
TLC, % predicted (SD) 126 (21)
RV, % predicted (SD) 192 (51)
DLCO, % predicted (SD) 45 (16)
KCO, % predicted (SD) 63 (19)
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The oximetry measurements between the first and second
recording showed high correlations with intra-class coeffi-
cients of 0.74e0.88. This high reproducibility in patterns of
desaturation (p < 0.0001) was noted in all 4 comparison
indices, on consecutive recordings within 2 weeks of each
another (Table 2). Also, we found very close agreement
between the respiratory clinician investigators and the
respiratory sleep specialist in their assessment of the oxi-
meter tracings (Kappa: 0.86; 95% CI: 0.78e0.94). When
evaluating only those with significant nocturnal desatura-
tion, with or without evidence of sleep apnea, agreement
remained very close (Kappa: 0.65; 95% CI: 0.45e0.86).Prevalence of nocturnal oxygen desaturation
A total of 49 patients (38%; 95% CI: 30%e47%) met our
criterion for nocturnal desaturators without evidence of
sleep apnea. Among these 49 patients, 5 would have beenTable 2 Test-retest reliability of nocturnal oximetry in
COPD.
Intra-class coefficients
of correlation
p value
Desaturation index 0.88 <0.0001
Baseline saturation 0.76 <0.0001
Average saturation 0.74 <0.0001
% recording time with
saturation < 90%
0.84 <0.0001classified as non-desaturators if only the first oximetry had
been considered. Twenty 20 patients (16%) were desatu-
rators with suspected sleep apnea. Of the remaining 59
patients (46%) who did not have significant nocturnal
desaturation, 12 had at least one tracing suggestive of
sleep apnea. Therefore, 32 patients (20 þ 12; 25%; 95%
CI: 18%e33%) had at least one oximetry tracing suggestive
of sleep apnea.
Predictors of nocturnal oxygen desaturation
The baseline clinical characteristics among the three groups
were similar with the exception of smoking history, body
mass index (Table 3). In the physiological measures they
differed only in baseline PaCO2 (Table 4). These differences
were only apparent in the desaturators suspected of having
sleep apnea. The non-desaturators and the desaturators
without evidence of sleep apnea were similar in all charac-
teristics. The comparisons of nocturnal oximetry results are
summarized in Table 5. The observed differences are from
our classification of patients that we defined a priori.
In the logistic regression analyses, baseline saturation at
night was one of the only 2 significant predictors of
nocturnal oxygen desaturation in patients without evidence
of sleep apnea (odds ratio, by 1% decrement in baseline
saturation: 1.48; 95% CI: 1.22e1.80). The other significant
predictor (PaCO2) was unlikely to be of value as the absolute
differences (42 versus 43 mmHg) fell within the precision
range of the test.19
Discussion
In this cross-sectional study across 5 clinical sites, almost
40% of patients with moderate-to-severe COPD who would
not qualify for LTOT exhibited meaningful nocturnal oxygen
desaturation without evidence of sleep apnea. Given that
this desaturation could not be predicted from simple
anthropometric or lung function measures, nocturnal
saturation should be measured directly in this population.
The study that best compares to ours in terms of inclusion
and exclusion criteria was that of Lewis et al.20 In this small
study, nocturnal oximetry was performed in 59 patients with
COPD who did not qualify for LTOT. Their study protocol was
different from ours in that patients suspected of having
obstructive sleep apnea on the basis of typical symptoms
and an Epworth Sleepiness score  10 were excluded.
Twenty-nine (49%) were desaturators. Our results are
therefore very consistent with theirs and confirms the high
prevalence of nocturnal desaturators among patients with
COPD not qualifying for LTOT. Our study adds to the preci-
sion of the prevalence estimate by our evaluating a larger
sample size (59 patients in Lewis’ vs. 128 in ours).
Although the definition of nocturnal oxygen desaturation
(i.e., 30% of the recording time with an oxygen
saturation < 90%) adopted in this study is arbitrary, it is
nevertheless widely used, with some variation, in Canada21
and Europe.11 Given the absence of recommendations
regarding the number of recordings and the night-to-nigh
variability in nocturnal desaturation in COPD reported by
Lewis et al.22, we elected to obtain 2 nocturnal recordings on
each patient. This variability may be of importance when the
Table 3 Comparisons of baseline clinical characteristics.
No significant nocturnal
desaturation (n Z 59)
Significant nocturnal
desaturation without
evidence of sleep
apnea (n Z 49)
Significant nocturnal
desaturation with
evidence of sleep
apnea (n Z 20)
P value
Age, years (SD) 71 (8) 68 (7) 69 (9) 0.21
Gender (% male) 39 (66%) 24 (49%) 16 (80%) 0.04
Body mass index, kg/m2 (SD) 24 (5) 25 (5) 29 (7) 0.003
Current smokers (%) 8 (13%) 10 (20%) 3 (15%) 0.62
Pack-years (SD) 49 (24) 49 (19) 67 (34) 0.004
Theophyline 14 (24%) 5 (10%) 2 (10%) 0.12
Tiotropium 49 (83%) 41 (84%) 14 (70%) 0.37
Long acting beta-agonists
(LABA) alone
14 (23%) 15 (31%) 6 (30%) 0.70
Inhaled steroids (ICS) alone 3 (5%) 2 (4%) 0 (0%) 0.60
Combinations (LABA þ ICS) 28 (47%) 23 (47%) 7 (35%) 0.60
Prednisone 3 (5%) 3 (6%) 1 (5%) 0.97
Nocturnal oxygen in COPD 1335time spent below a saturation < 90% approaches the diag-
nostic threshold. For instance, an individual could spend 28%
and 32% of the recording time with an oxygen saturation
< 90% during a first and second night respectively. Such an
individual would be classified as a non-desaturator after the
former and a desaturator following the latter.
The rationale of assessing for nocturnal desaturation in
COPD is that it may decrease survival.23 In addition, its
treatment with supplemental oxygen may prolong life. This
suggestion comes from an indirect comparison of the British
Medical Research Council Study24 and the National Heart Lung
and Blood Institute’s trial25 suggesting that patients receiving
12 h of oxygen/day (most of which was provided at night) was
associatedwithbetter survival than those receiving nooxygen
therapy. However, these were severely hypoxemic patients
with a daytime PaO2 55 mmHg who would qualify for LTOT.
To date, only two randomized trials directly addressed the
issue of nocturnal oxygen therapy in patients with COPD with
significant nocturnal oxygen desaturation who would not
qualify for LTOT26,27 and a meta-analysis of these two studiesTable 4 Comparisons of arterial blood gases and pulmonary fun
No significant nocturnal
desaturation (n Z 59)
Significant
desaturati
of sleep ap
pH 7.43 (0.02) 7.42 (0.03
PaCO2 42 (4) 42 (5)
PaO2 66 (3) 64 (4)
Hemoglobin 146 (14) 145 (13)
Hematocrit 0.44 (0.04) 0.44 (0.04
FEV1% 35 (10) 36 (12)
FVC % 79 (23) 81 (19)
FEV1/FVC 35% (9) 35% (12)
FRC % 167 (36) 163 (31)
TLC % 128 (23) 126 (18)
RV % 194 (57) 192 (44)
DLCO % 45 (14) 42 (17)
KCO, % predicted (SD) 63 (18) 59 (20)concluded that nocturnal oxygen therapy had no effect on
survival (pooled odds ratio: 0.97; 95% CI: 0.41e2.31).28
However, the number of patients randomized in these 2
trials was small and the issue remains unresolved.
Also, determination of nocturnal desaturation may be
important because it may impact on sleep quality and/or
health-related quality of life. However, this hypothesis is not
supported by Lewis’ findings who could not demonstrate any
association between nocturnal desaturation and impairment
of health-related quality of life, sleep quality or daytime
function.20 The effect of nocturnal oxygen therapy on
quality of life and sleep quality was directly addressed in
a single randomized, placebo-controlled cross-over trial
involving 19 daytime normoxemic COPD patients with
nocturnal oxygen desaturation.29 The authors observed
significant differences only in the sleep dimension of the
Nottingham Health Profile. All the other dimensions of the
Nottingham Health Profile, SF-36 and St-George’s Respira-
tory Questionnaire showed no difference between nocturnal
oxygen and placebo. Unfortunately, the interpretation ofction tests results.
nocturnal
on without evidence
nea (n Z 49)
Significant nocturnal
desaturation with evidence of
sleep apnea (n Z 20)
P value
) 7.41 (0.03) 0.06
46 (6) 0.003
64 (4) 0.07
142 (15) 0.69
) 0.45 (0.05) 0.56
36 (11) 0.37
69 (15) 0.08
40% (13) 0.17
159 (35) 0.68
121 (20) 0.42
185 (51) 0.84
55 (18) 0.02
74 (19) 0.02
Table 5 Comparisons of nocturnal oximetry results.a
No significant
nocturnal
desaturation
(n Z 59)
Significant nocturnal
desaturation without
evidence of sleep
apnea (n Z 49)
Significant nocturnal
desaturation with
evidence of sleep
apnea (n Z 20)
P value
Recording time (hours) 7.4 (1.4) 7.4 (1.3) 7.7 (1.3) 0.63
Desaturation index 5 (6) 5 (3) 21 (16) < 0.0001
Baseline saturation 92 (1) 89 (2) 88 (4) < 0.0001
Average saturation 89 (2) 86 (3) 85 (3) < 0.0001
% recording time with
saturation 90%
9 (8) 57 (27) 69 (24) < 0.0001
a Only the results of the second oximetry are shown.
1336 Y. Lacasse et al.results of both Lewis’ and Orth’s studies are limited by their
small sample size.
We did not study all our patients with respiratory poly-
somnography, an obvious study limitation. Nevertheless, the
results of our validation study suggested that home oximetry
has high negative predictive value for the diagnosis of sleep
apnea. This property is of particular interest in clinical
practice if the purpose of home oximetry is only to identify
those patients with nocturnal desaturation who could
benefit from nocturnal oxygen therapy. Given the shape of
the oxyhemoglobin dissociation curve, cyclical changes in
saturation in addition to the desaturations would be expec-
ted if sleep apnea existed. Nocturnal oximetry demon-
strating a steady tracing with non-periodic variation in
saturation throughout sleep may exclude sleep apnea.
Further validation is needed however. It is noteworthy that
in a recent survey of prescribing practices most respirologists
indicated that they would accept a diagnosis of nocturnal
oxygen desaturation on the basis of oximetry tracings.21
Our finding of a high prevalence of nocturnal oxygen
desaturation in patients with moderate-to-severe COPD not
qualifying for LTOT may be an indication of the need for
regular screening of this patient population using home oxi-
metry, especially as the benefits of administering nocturnal
oxygen to this population remains to be established.Acknowledgements
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